A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 1, 2007, Pages 97-103

  Herrera, Fernanda G ^a   Chan, Philip ^a   Doll, Corinne ^a   Milosevic, Michael ^a   Oza, Amit ^b   Syed, Amy ^a   Pintilie, Melania ^b   Levin, Wilfred ^a   Manchul, Lee ^a   Fyles, Anthony ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Celecoxib; Cervical cancer; Chemoradiation; Phase I II trial

Indexed keywords

BIOMARKERS; CHEMOTHERAPY; ONCOLOGY; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY;

CELECOXIB; CERVICAL CANCER; CHEMORADIATION; PHASE I-II TRIAL;

ENZYME INHIBITION;

CD31 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; KI 67 ANTIGEN;

ADULT; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; FATIGUE; FEMALE; FISTULA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; NAUSEA; NEUTROPENIA; OXYGEN TISSUE LEVEL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTOVAGINAL FISTULA; SEPSIS; SKIN MANIFESTATION; SYNCOPE; TISSUE PRESSURE; TUMOR OXYGENATION; UROGENITAL TRACT INFECTION; UTERINE CERVIX CARCINOMA; VAGINA NECROSIS; VOMITING;

ADULT; AGED; CELL HYPOXIA; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; EXTRACELLULAR FLUID; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; LEUKOPENIA; MIDDLE AGED; OXYGEN CONSUMPTION; PROSPECTIVE STUDIES; PYRAZOLES; RECTOVAGINAL FISTULA; REMISSION INDUCTION; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 33845627724     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.024     Document Type: Article

References (41)

1. Herrero R. Epidemiology of cervical cancer. Proceedings of NHI Consensus Development Conference on Cervix Cancer. Vol 1996: National Health Institute; 1996.
2. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
3. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
4. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
5. Eifel P.J., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol 22 (2004) 872-880
6. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48 (1998) 149-156
7. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20 (2002) 680-687
8. Harris A.L. Hypoxia-A key regulatory factor in tumour growth. Natl Rev Cancer 2 (2002) 38-47
9. Milosevic M., Fyles A., Hedley D., et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61 (2001) 6400-6405
10. Koki A.T., and Masferrer J.L. Celecoxib: A specific COX-2 inhibitor with anticancer properties. Cancer Control 9 (2002) 28-35
11. Kim H.J., Wu H.G., Park I.A., et al. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 16-20
12. Gaffney D.K., Holden J., Davis M., et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 1213-1217
13. Ryu H.S., Chang K.H., Yang H.W., et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76 (2000) 320-325
14. Kim S.H., Song S.H., Kim S.G., et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 130 (2004) 551-560
15. Nakata E., Mason K.A., Hunter N., et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58 (2004) 369-375
16. Raju U., Nakata E., Yang P., et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. Int J Radiat Oncol Biol Phys 54 (2002) 886-894
17. Ferrandina G., Ranelletti F.O., Legge F., et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: A pilot study. Clin Cancer Res 9 (2003) 4324-4331
18. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
19. Wong R.K., Fyles A., Milosevic M., et al. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: An evaluation of within and between tumor variability, probe position, and track depth. Int J Radiat Oncol Biol Phys 39 (1997) 405-412
20. Therasse P., Arbuck S.G., Eisenhauer E.A., et al., European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
21. Harris R.E., Alshafie G.A., Abou-Issa H., et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60 (2000) 2101-2103
22. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
23. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
24. Fyles A.W., Pintilie M., Kirkbride P., et al. Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis. Radiother Oncol 35 (1995) 107-117
25. Gaffney D.K. A Phase I-II study of COX-2 inhibitor Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128 [Abstract]. Int J Radiat Oncol Biol Phys 63 suppl. (2005) S93
26. Kirwan J.M., Symonds P., Green J.A., et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68 (2003) 217-226
27. Bachtiary B., Dewitt A., Pintilie M., et al. Comparison of late toxicity between continuous low-dose-rate and pulsed-dose-rate brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 63 (2005) 1077-1082
28. Brown J.M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52 (1979) 650-656
29. Pigott K.H., Hill S.A., Chaplin D.J., et al. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol 40 (1996) 45-50
30. Cooper R.A., West C.M., Logue J.P., et al. Changes in oxygenation during radiotherapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 45 (1999) 119-126
31. Milosevic M., Fyles A., Hedley D., et al. The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14 (2004) 249-258
32. Taghian A.G., Abi-Raad R., Assaad S.I., et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications. J Clin Oncol 23 (2005) 1951-1961
33. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Natl Med 10 (2004) 145-147
34. Kitamura T., Itoh M., Noda T., et al. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 109 (2004) 576-580
35. Chulada P.C., Thompson M.B., Mahler J.F., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60 (2000) 4705-4708
36. Tiano H.F., Loftin C.D., Akunda J., et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62 (2002) 3395-3401
37. Shin Y.K., Park J.S., Kim H.S., et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65 (2005) 9501-9509
38. Pyo H., Choy H., Amorino G.P., et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7 (2001) 2998-3005
39. Kim G.E., Kim Y.B., Cho N.H., et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clin Cancer Res 10 (2004) 1366-1374
40. Dannenberg A.J., Lippman S.M., Mann J.R., et al. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
41. Moraitis D., Du B., De Lorenzo M.S., et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: Evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65 (2005) 664-670